vida: extract claims from 2026-05-05-fda-oral-wegovy-approval-oasis4-jan2026

- Source: inbox/queue/2026-05-05-fda-oral-wegovy-approval-oasis4-jan2026.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -52,3 +52,10 @@ Review frames GLP-1RAs as 'at the intersection of medical innovation and psychol
 **Source:** Timmerman Report regulatory analysis, November 2025
 
 Timmerman Report documents that semaglutide labels do not include warnings for restrictive eating disorder risk, and no safety database exists for monitoring GLP-1-induced eating disorders. The regulatory gap extends beyond screening protocols to include labeling and post-market surveillance infrastructure.
+
+
+## Supporting Evidence
+
+**Source:** FDA oral Wegovy label, January 2026
+
+FDA label for oral Wegovy contains NO eating disorder warning or screening requirement despite known pharmacovigilance signal (aROR 4.17-6.80). Label includes standard thyroid C-cell tumor boxed warning but explicitly REMOVED suicidal behavior/ideation warning in 2026 review after finding no causal link. This regulatory asymmetry—removing psychiatric warnings while maintaining zero ED action—confirms the screening gap is structural/regulatory, not knowledge-based.

domains/health/glp1-year-one-persistence-doubled-2021-2024-supply-normalization.md

@@ -10,15 +10,17 @@ agent: vida
 scope: correlational
 sourcer: BCBS Health Institute
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[divergence-glp1-economics-chronic-cost-vs-low-persistence]]"]
-supports:
+supports: ["GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements"]
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
+reweave_edges: ["GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|supports|2026-04-09", "Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment|related|2026-04-28"]
-reweave_edges:
+related: ["Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints"]
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|supports|2026-04-09
-- Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment|related|2026-04-28
-related:
-- Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment
 ---
 
 # GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
 
 BCBS Health Institute and Prime Therapeutics analyzed real-world commercial insurance data showing one-year persistence rates for obesity-indicated, high-potency GLP-1 products increased from 33.2% in 2021 to 34.1% in 2022, 40.4% in 2023, and 62.6% in 2024. Semaglutide (Wegovy) specifically tracked nearly identically: 33.2% (2021) → 34.1% (2022) → 40.0% (2023) → 62.7% (2024). Adherence during the first year improved from 30.2% (2021) to 55.5% (2024 H1). The report attributes this improvement to two primary drivers: resolution of supply shortages that plagued 2021-2022 and 'improved patient management' (though the specific mechanisms are not detailed). This represents a genuine shift in the short-term adherence pattern and compresses the population-level signal timeline for GLP-1 impact. However, this data is limited to commercial insurance populations, which have better access and support than Medicaid, Medicare, or uninsured populations, suggesting the improvement may not generalize to the populations most in need of obesity treatment.
+
+## Extending Evidence
+
+**Source:** Novo Nordisk oral Wegovy launch, January 2026
+
+Oral formulation launch creates second persistence improvement pathway beyond supply normalization. Injection barrier removal should improve adherence for needle-averse segment, potentially pushing year-one persistence above the 47% benchmark established for injectable semaglutide. Manufacturing at North Carolina facilities indicates supply chain maturity.

entities/health/oral-wegovy.md

@@ -0,0 +1,33 @@
+# Oral Wegovy (Semaglutide Pill)
+
+**Type:** GLP-1 receptor agonist, oral formulation  
+**Manufacturer:** Novo Nordisk  
+**Status:** FDA approved January 2026  
+**Indication:** Weight management in adults with obesity or overweight + ≥1 comorbidity; cardiovascular event risk reduction in adults with CVD + obesity/overweight
+
+## Clinical Profile
+
+**OASIS 4 Trial (Phase III, 64 weeks, n=307):**
+- Weight loss: 16.6% with oral Wegovy + lifestyle intervention vs. 2.7% placebo
+- Serious adverse events: 3.9% treatment vs. 8.8% placebo (lower in treatment arm)
+- Common adverse reactions: nausea, vomiting, diarrhea
+- Efficacy comparable to injectable formulation for this population
+
+## Safety Label
+
+- **Boxed warning:** Thyroid C-cell tumor risk (standard GLP-1 class warning)
+- **NO eating disorder warning** in label
+- **Suicidal behavior/ideation warning REMOVED** in 2026 FDA review (no causal link found)
+- No eating disorder screening requirement in prescribing information
+
+## Market Significance
+
+- First oral GLP-1 formulation for weight management
+- Eliminates injection barrier, expanding addressable patient population
+- Manufacturing at North Carolina facilities
+- Launched January 2026
+
+## Timeline
+
+- **2026-01-01** — FDA approval for weight management and cardiovascular risk reduction
+- **2026-01-01** — Commercial launch with North Carolina manufacturing

inbox/archive/health/2026-05-05-fda-oral-wegovy-approval-oasis4-jan2026.md

@@ -7,10 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: medium
 tags: [glp-1, semaglutide, wegovy, oral-glp1, fda-approval, oasis4, access, eating-disorder-label]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content